Patents by Inventor Sandra Zurawski

Sandra Zurawski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9562104
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: February 7, 2017
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Publication number: 20160331825
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 17, 2016
    Inventors: SangKon OH, Sandra ZURAWSKI, Gerard ZURAWSKI
  • Patent number: 9339556
    Abstract: The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: May 17, 2016
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
  • Patent number: 9315580
    Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: April 19, 2016
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, Eynav Klechevsky, SangKon Oh
  • Publication number: 20160022792
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: August 6, 2015
    Publication date: January 28, 2016
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Patent number: 9234040
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 12, 2016
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 9109011
    Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: August 18, 2015
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes, Sandra Zurawski, SangKon Oh
  • Patent number: 9102734
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: August 11, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Patent number: 9102730
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 11, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Publication number: 20140322214
    Abstract: The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells.
    Type: Application
    Filed: April 29, 2014
    Publication date: October 30, 2014
    Applicant: Baylor Research Institute
    Inventors: Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Ling Ni
  • Publication number: 20140234344
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: January 27, 2014
    Publication date: August 21, 2014
    Applicant: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Publication number: 20140227268
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 14, 2014
    Applicant: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Sangkon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
  • Patent number: 8728481
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: May 20, 2014
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, SangKOn Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
  • Publication number: 20140134168
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 15, 2014
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Publication number: 20140120617
    Abstract: The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
    Type: Application
    Filed: June 26, 2013
    Publication date: May 1, 2014
    Inventors: JACQUES F. BANCHEREAU, SANGKON OH, GERARD ZURAWSKI, SANDRA ZURAWSKI, DAPENG LI
  • Patent number: 8586052
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: November 19, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 8481314
    Abstract: The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: July 9, 2013
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
  • Patent number: 8449888
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 28, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Publication number: 20130053271
    Abstract: A flexible method for making multiplexed assays for antigen-specific antibody responses is disclosed herein. The method of the present invention comprises incubation of a substrate or a set of beads coated with a dockerin or a cohesin protein with a cohesin or dockerin-antigen fusion proteins to attach the fusion protein essentially irreversibly by non-covalent interaction. The present invention enables the use of one dockerin- or cohesin-coated bead for multiple sets of cohesin- or dockerin-antigens, obviating the need to directly chemically couple new antigens to new beads.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Sandra Zurawski
  • Publication number: 20120315269
    Abstract: Compositions and methods for inhibiting effector CD8+ T cell priming by Langerhans cells (LCs), together with promotion of the production of IL-4 and IL-10 are disclosed herein. The findings of the present indicate that immunoglobulin-like transcript (ILT) inhibitory receptors expressed on dermal CD14+ DCs represent natural counterparts of the anti-CD8 mAbs. Accordingly, blocking ILT2 or ILT4 on dermal CD14+ DCs enhanced the generation of effector polyfunctional CD8+ T cells. Conversely, soluble ILT2 and ILT4 act as CD8-antagonists that inhibit effector CD8+ T cell priming by LCs, together with promoting the production of IL-4 and IL-10. The results presented herein indicate that ILT receptor family members can skew the polarization of CD8+ T cell responses and strategies to block ILT expression on dendritic cells (DCs) may be useful to augment dendritic cell function to enhance responses to cancer or chronic viral infections.
    Type: Application
    Filed: May 7, 2012
    Publication date: December 13, 2012
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Eynav Klechevsky, Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski